Prostate cancer and prostatic diseases · 2026
Efficacy and safety of darolutamide plus androgen-deprivation therapy in Black patients with metastatic hormone-sensitive prostate cancer from the phase 3 ARANOTE trial.
СтатьяКлиническое исследование III фазыРандомизированное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Trinh Quoc-Dien, George Daniel J, Shore Neal, Vjaters Egils, Olmos David, de Santana Gomes Andrea Juliana P, de Andrade Mota Augusto Cesar, Littleton Natasha, Srinivasan Shankar, Verholen Frank, Haresh Kunhi Parambath, Saad Fred
Аннотация
BACKGROUND: This analysis reports efficacy and safety data in the subgroup of Black patients from the ARANOTE phase 3 trial.
METHODS: Patients starting on androgen-deprivation therapy (ADT) were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo. Of the total ARANOTE population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were Black.
RESULTS: In Black patients, darolutamide + ADT improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% vs ADT alone, consistent with the overall population.
CONCLUSIONS: In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS.
METHODS: Patients starting on androgen-deprivation therapy (ADT) were randomised 2:1 to receive darolutamide 600 mg twice daily or placebo. Of the total ARANOTE population (N = 669), 65 patients (10%; darolutamide, n = 41; placebo, n = 24) were Black.
RESULTS: In Black patients, darolutamide + ADT improved radiological progression-free survival (rPFS), reducing the risk of radiological progression or death by 49% vs ADT alone, consistent with the overall population.
CONCLUSIONS: In Black patients from ARANOTE, darolutamide was associated with improvement in rPFS.